Metformin Therapy and Breast Cancer Incidence in the Hail Region
Abstract
Metformin is a drug used to treat patients with type 2 diabetes, especially those who suffer from obesity. It is also used in treating women with polycystic ovary syndrome (PCOS). This disease has been shown to be related to insulin resistance and multiplied blood sugar ranges. Further, it has been found that using metformin improves these women's menstrual cycles and ovulation rates. Methods: A structured questionnaire will be conducted to determine the prevalence of breast cancer among women using metformin in the Hail region. Result: The incidence of breast cancer among women using metformin in the Hail region is very low. Conclusions: According to previous findings, metformin has been linked to lower breast cancer risk in women with type 2 diabetes. Furthermore, the findings of this study have corroborated the literature for the same by indicating a substantial connection between metformin use and a lower risk of breast cancer in women with type 2 diabetes.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.